Should tamoxifen users be screened for endometrial lesions?

Lancet

Volumn 351, Issue 9097, 1998, Pages 155-157

  Neven, P ^a   Vergote, I ^a  

^a Saint Jean Clinic of Brussels   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

TAMOXIFEN;

BREAST CANCER; CANCER SCREENING; COST BENEFIT ANALYSIS; DRUG CARCINOGENICITY; ENDOMETRIUM CANCER; FEMALE; HIGH RISK PATIENT; HUMAN; PRIORITY JOURNAL; SHORT SURVEY;

EID: 0032539466     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(05)78216-7     Document Type: Note

References (12)